SYS6006 Plus Enlonstobart for Advanced Solid Tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a new drug called SYS6006 to an existing cancer treatment (enlonstobart) works better than enlonstobart alone for advanced solid tumors that cannot be surgically removed. The goal is to see if the combination helps shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (cancer that is not blood-based) that has spread or cannot be removed by surgery
- Your tumor can be measured on imaging scans (at least one visible lesion)
- You are in good enough health to tolerate treatment (ECOG score of 0-2, meaning you can do light to moderate activities)
- Your major organs and bone marrow are functioning well enough based on recent blood tests
- You are expected to live at least 3 more months
- If you can have children, you agree to use reliable birth control during and after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This clinical trial tests a new investigational drug (SYS6010) combined with another drug (SYH2051) or given alone, compared to standard chemotherapy, for advanced breast cancer and other solid tumors that have a specific protein called EGFR. The goal is to see if this treatment can help shrink tumors or slow their growth.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.